Propanc Biopharma, Inc.

Propanc Biopharma provided a scientific comparison of its lead candidate PRP with RAS-targeted approaches, highlighting PRP's unique mechanism for treating aggressive, treatment-resistant cancers like PDAC. The company plans to file a clinical trial application in Q4 for a Phase 1b study in advanced cancer patients, aiming to demonstrate PRP's potential as a long-term treatment option. PRP, which has FDA Orphan Drug Designation for pancreatic cancer, works by promoting cancer cell differentiation and reversing EMT, offering a non-cytotoxic approach.

Propanc Biopharma announced compelling new preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC). The data showed over 90% mean tumor growth inhibition and a more than 2.5-fold extension in median overall survival in advanced PDAC models. The company is accelerating its Phase 1b, First-In-Human study in advanced solid tumors, with a clinical trial application expected in Australia in the coming months.

Propanc Biopharma, Inc. announced the completion of the first $500,000 tranche of its share repurchase program within 30 days of its commencement. The company stated its belief that its shares are significantly undervalued, especially as it progresses towards a world-first Phase 1b, First-In-Human study for 40-45 advanced cancer patients in Australia. Propanc intends to continue the buyback program, emphasizing its commitment to reflecting shareholder equity.

Propanc Biopharma, Inc. announced that Annie Van Broekhoven retired and stepped down from its Board of Directors effective July 8, 2026. Concurrently, the Board appointed Carlo Campiciano to fill the vacancy. Mr. Campiciano brings extensive experience as a qualified accountant, having served as CFO and Company Secretary of MedAdvisor Limited, where he played a key role in capital raising, ASX listing, and international expansion.

Propanc Biopharma, Inc. announced the initiation of a share repurchase program, authorizing an initial tranche of up to $500,000 over the next 30 days. The company's CEO, Mr. James Nathanielsz, stated that the program reflects confidence in the company's transformative stage of development, particularly with its lead asset, PRP, advancing into clinical trials. The program aims to reflect the true value of shareholders' equity and may continue beyond the initial 30-day period.

Propanc Biopharma, Inc. announced that its CEO, James Nathanielsz, toured a European CDMO's GMP facility to prepare for the production of its lead asset, PRP. This production is crucial for the upcoming Phase 1b, First-In-Human study involving 30-40 advanced cancer patients with solid tumors. Key timelines include preproduction in August 2026, an engineering run in October 2026, and GMP manufacture commencing in December 2026, with a Phase 1B clinical trial application in Australia planned for submission in 2026.

Propanc Biopharma, Inc. has approved a share repurchase program, authorizing the company to buy back up to $5.0 million of its common stock. This decision reflects management's belief that the company is significantly undervalued, especially given recent advancements of its lead asset, PRP, towards a pivotal Phase 1b clinical study for metastatic cancer. The company also highlighted its US FDA Orphan Drug Designation for pancreatic cancer, providing seven-year market exclusivity post-approval, and strategic partnerships. The program aims to enhance shareholder value and signals management's confidence in the company's long-term prospects.

Propanc Biopharma's CEO, James Nathanielsz, attended a keynote address on "Rejuvenation and Health: Science for an Ageing Society" at the University of Granada, featuring renowned scientist Dr. Juan Carlos Izpisúa. Nathanielsz highlighted that Propanc's research into proenzymes for age-related diseases, fibrosis, diabetes, and cancer aligns with this pioneering field. The company also announced that its lead asset, PRP, is on schedule to enter a Phase 1b, First-In-Human study in advanced cancer patients, with ongoing collaborations with the Universities of Granada and Jaén.

Propanc Biopharma, Inc. announced its intention to file a Clinical Trial Application (CTA) in Australia later this year for a Phase 1b, First-In-Human study of its lead asset, PRP. This study will involve 30-40 advanced cancer patients with solid tumors, utilizing an intravenous formulation of PRP administered once weekly. Following the completion of Phase 1, the company plans to conduct two Phase 2 studies, each with 60 patients, targeting pancreatic and ovarian cancers. The CEO also highlighted broader advancements in pancreatic cancer treatment, reinforcing the company's focus on biologically informed strategies.

Propanc Biopharma engaged a European Contract and Development Manufacturing Organization (CDMO) for GMP manufacturing of its lead asset, PRP, for an upcoming Phase 1b First-In-Human clinical study. This pivotal step aims to advance PRP, a proenzyme therapy for advanced solid tumors, into early-stage clinical development. The company plans to file the clinical trial application later this year for the study involving 30-40 advanced cancer patients. PRP, which induces differentiation of cancer cells, previously received USFDA Orphan Drug Designation for pancreatic cancer.